Key terms

About HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest HALO news

Mar 08 7:26am ET TD Cowen Reaffirms Their Buy Rating on Halozyme (HALO) Feb 29 5:47am ET Buy Rating Affirmed for Halozyme on Strong ENHANZE Technology Prospects and Robust Partnership Pipeline Feb 29 5:41am ET Halozyme initiated with an Outperform at TD Cowen Feb 26 7:30am ET Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), Halozyme (HALO) and Eli Lilly & Co (LLY) Feb 26 12:10am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Immuneering (IMRX), Halozyme (HALO) and Repligen (RGEN) Feb 21 8:11am ET Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), NeoGenomics (NEO) and Ardelyx (ARDX) Feb 21 6:09am ET Halozyme price target raised to $50 from $48 at H.C. Wainwright Feb 21 1:11am ET Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC), GeneDx Holdings (WGS) and Halozyme (HALO) Feb 20 9:30pm ET Analysts Offer Insights on Healthcare Companies: Halozyme (HALO) and AbCellera Biologics (ABCL) Feb 20 4:10pm ET Halozyme sees FY24 royalty revenue $500M-$525M Feb 20 4:03pm ET Halozyme announces new $750M share repurchase plan Feb 20 4:03pm ET Halozyme backs FY24 adjusted EPS view $3.55-$3.90, consensus $3.51 Feb 20 4:02pm ET Halozyme reports Q4 adjusted EPS 82c, consensus 82c Feb 14 12:15pm ET Buy Rating Affirmed for Halozyme: Projected Royalty Revenue and EBITDA Surge to $1 Billion by 2027 Feb 13 7:20am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: AptarGroup (ATR), Halozyme (HALO) and Bausch Health Companies (BHC) Jan 29 4:30pm ET Halozyme announces Takeda received EC approval for HYQVIA Jan 22 3:10pm ET Analysts Conflicted on These Healthcare Names: Generation Bio (GBIO), RegenXBio (RGNX) and Halozyme (HALO) Jan 22 1:40pm ET Analysts Offer Insights on Healthcare Companies: ATAI Life Sciences (ATAI), Halozyme (HALO) and Natera (NTRA) Jan 22 1:31pm ET Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), Vor Biopharma (VOR) and Clearside Biomedical (CLSD) Jan 22 12:35pm ET Buy Rating for HALO: Long-Term Royalty Growth and Robust Financial Outlook Jan 18 8:33am ET Halozyme announces approval for Vydura in Japan Jan 18 6:14am ET Halozyme price target lowered to $48 from $61 at H.C. Wainwright Jan 05 7:55am ET Piper Sandler Remains a Buy on Halozyme (HALO) Jan 05 5:56am ET Buy Rating Affirmed for Halozyme: A Balanced View Amid Forecast Adjustments and Market Growth Potential Dec 26 7:46am ET Halozyme price target lowered to $59 from $61 at Morgan Stanley Dec 21 6:00am ET Analysts Conflicted on These Healthcare Names: Halozyme (HALO), Immunovant (IMVT) and Henry Schein (HSIC) Dec 20 5:24pm ET Halozyme price target lowered to $45 from $46 at Goldman Sachs Dec 15 6:22am ET Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Clearside Biomedical (CLSD) and Halozyme (HALO) Dec 15 5:29am ET Buy Rating on Halozyme Stock: Long-term Prospects Outweigh Near-term Revenue Dip

No recent news articles are available for HALO

No recent press releases are available for HALO

HALO Financials

1-year income & revenue

Key terms

HALO Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

HALO Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms